AFP and hepatocellular carcinoma: In recent years, PIVKA‐II is considered to be a novel serological marker for HCC.6, 23 Our results indicated that PIVKA‐II was significantly higher in AFP‐NHCC patients and were useful for distinguishing AFP‐NHCC from cirrhosis and controls, and the sensitivity was 65.4%, the specificity was 84.6%, which was consistent with previous research results.23 In our research, miR‐363‐5p was the most effective indicator (AUC = 0.901) for the diagnosis of AFP‐NHCC than miR‐765 (AUC = 0.838) and PIVKA‐II (AUC = 0.749), but its sensitivity (78.5%) was unsatisfactory.